Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

► Med - Pharmacology > Dopamine and Serotonin > Flashcards

Dopamine and Serotonin Flashcards

1
Q

Sumatriptan target and function

A

5‐HT1D receptor Agonist - treats migraines

Inhibition of inflammatory mediator release Cerebrovasconstriction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Sumatriptan indication

A

Migraines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Sumatriptan toxicity

A

Coronary vasoconstriction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Sumatriptan contraindication

A

Coronary artery disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How is the 5-HT1D family of receptors is manipulated to treat migraine?

A

5-HT1D agonists like sumatriptan inhibits inflammatory mediator release with cerebral vasoconstriction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How are 5-HT1A receptors manipulated pharmacologically for treatment of anxiety and depression?

A

5-HT1A agonists like buspirone lead to the activation of post‐synaptic receptors in cortical regions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How are 5-HT3 receptors manipulated pharmacologically for the treatment of chemotherapy-induced nausea and emesis?

A

There are 5-HT3 antagonists like ondansetron that reduce cancer treatment related emesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How is the 5-HT4 receptor manipulated for treatment of GI disorders?

A

5-HT4 agonists like mosapride will stimulate ACh release in the myenteric plexus which treats things like gastroparesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Buspirone target and function

A

5-HT1A partial agonist

Activation of post‐synaptic receptors in cortical regions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Buspirone indication

A

Anxiety

Depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Buspirone toxicity

A

Early increase in anxiety

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

5-HTP function

A

5-HT precursor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

5-HTP indication

A

Depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Risperidone target and function

A

5-HT2A/2C antagonist and D2/3 antagonist
Suppresses DA release in mesolimbic pathway, but
increases DA release in mesocortical pathway.

Increased activity in mesolimbic causes hallucinations
Decreased activity in mesocortical causes poor emotional affect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Risperidone indication

A

Schizophrenia with psychosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Risperidone toxicity

A

Weight gain

Akithisia - restlessness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Ondasetron target and function

A

5-HT3 antagonist

Reduces emesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Ondasetron indication

A

Chemotherapy induced emesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Ondasetron toxicity

A

None. Well tolerated in patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Fluoxetine/Sertraline target and function

A

SSRI

Increases 5-HT (serotonin) post-synaptic receptor activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Fluoxetine/Sertraline indication

A 
Depression
OCD
Anxiety
Panic disorder
PTSD
Social phobia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Fluoxetine/Sertraline toxicity

A

Sexual dysfunction

Insomnia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Fluoxetine/Sertraline contraindications

A

MAO inhibitors as it can cause “serotonin syndrome”

24
Q

L-DOPA effect

A

DOPA precursor

25
Q

L-DOPA indication

A

Parkinson’s Disease

26
Q

L-DOPA toxicity

A

Arrhythmia

Dyskinesia

27
Q

Carbidopa effect

A

Inhibits AADC in peripheral tissue but cannot cross BBB.

Used with L-DOPA to minimize peripheral DOPA

28
Q

Carbidopa indication

A

Concurrent rx with L‐DOPA to reduce peripheral DA production to protect the CV system

29
Q

Carbidopa toxicity

A

Augments SE of L‐DOPA in CNS

30
Q

Selegiline target and effect

A

MAO-B inhibitor to increase DOPA

31
Q

Selegiline indication

A

Low dose: Parkinson’s Disease

High dose: Depression

32
Q

Selegiline toxicity

A

Potential for hypertensive crisis

33
Q

Bromocriptine target and effect

A

D2 agonist
Post synaptic activation in basal ganglia, may also be neuroprotective so best used early in disease. Leads to increased DOPA

34
Q

Bromocriptine indication

A

Parkinson’s Disease

35
Q

Bromocriptine toxicity

A

Arrhythmia

Dyskinesia

36
Q

Tolcapone target and effect

A

Inhibits COMT breakdown of DOPA

37
Q

Tolcapone indication

A

Parkinson’s Disease

38
Q

Tolcapone toxicity

A

Prolongs and increases effect of L‐DOPA, reduces “off” time, can reduce required L‐DOPA dose

39
Q

Tolcapone contraindication

A

Liver failure

40
Q

Haloperidol target and effect

A

D2 antagonist

41
Q

Haloperidol indication

42
Q

Haloperidol toxicity

A

Extra- pyramidal motor disturbances

43
Q

Methylphenidate target and effect

A

Increased DA release in frontal cortex

44
Q

Methylphenidate indication

45
Q

Methylphenidate toxicity

A

Tachycardia

46
Q

Methylphenidate contraindication

A

Tricyclic antidepressants

47
Q

Metaclopramide target and effect

A

D2 antagonist

48
Q

Metaclopramide indication

A

Chemotherapy‐induced‐ and post‐op nausea and vomiting

49
Q

Metaclopramide toxicity

50
Q

Metaclopramide contraindication

A

Long term prescription

51
Q

Trazadone target and effect

A

5‐HT2A/2C antagonist + SSRI

52
Q

Trazadone indication

A

Anxiety

Depression

53
Q

Trazadone toxicity/contraindication

A

Warning of suicidality in young adults at initiation of treatment

Contraindication: MAO inhibitors

54
Q

Mosapride/Cisapride target and effect

A

5‐HT4 receptor agonist

Promotes GI motility

55
Q

Mosapride/Cisapride indication

A

Gastroparesis

56
Q

Mosapride/Cisapride toxicity

A

Prolonged QT syndrom

► Med - Pharmacology (74 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions